Skip to main content

Table 3 Proportion of self-reported treated malaria episodes in which an anti-malarial currently recommended by the Ugandan MOH was used, by trimester of pregnancy

From: Patterns of anti-malarial drug treatment among pregnant women in Uganda

1st Trimester TOTAL
(n = 126 episodes*)
(95% CI)+
Currently recommended   
Quinine monotherapy; n (%) 7 (5.6) (2.5, 10.7)
Not currently recommended 119 (94.4) (89.3, 97.5)
SP monotherapy; n (%) 29 (23.0)  
Chloroquine monotherapy; n (%) 18 (14.3)  
SP+Chloroquine; n (%) 6 (4.8)  
Any AL; n (%) 53 (42.1)  
AL alone; n 26  
AL +1 other anti-malarial1; n 21  
AL + 2 or more other anti-malarials2; n 6  
Other; n (%) 13 (10.3)  
2 nd or 3 rd Trimester TOTAL
(n = 478 episodes*)
 
Currently recommended 144 (30.1) (26.1, 34.3)
AL alone; n (%) 113 (23.6)  
Quinine monotherapy; n (%) 28 (5.9)  
AL + quinine** 3 (0.6)  
Not currently recommended 334 (69.9) (65.6, 73.9)
SP monotherapy; n (%) 132 (27.6)  
AL +1 other anti-malarial3; n 78 (16.3)  
Chloroquine monotherapy; n (%) 31 (6.5)  
SP+Chloroquine; n (%) 23 (4.8)  
AL + 2 or more other anti-malarials4; n 13 (2.7)  
SP+Quinine 5 (1.1)  
Other; n (%) 52 (10.9)  
Any use of a currently recommended anti-malarial***; n (%) 240 (50.2) (45.7, 54.7)
Any use of AL; n (%) 207 (43.3)  
Any use of quinine; n (%) 33 (6.9)  
  1. AL: Artemether-lumefantrine
  2. SP: Sulphadoxine-pyrimethamine
  3. +95% Confidence Interval around the proportion
  4. *Excludes 33 episodes that were not treated; 1st trimester = 8 episodes; 2nd trimester = 25 episodes
  5. **Possibly correct depending on clinical circumstances
  6. ***Includes use of recommended drug combined with a non-recommended drug
  7. 1AL plus: SP (n = 16); Chloroquine (n = 3); Quinine (n = 2)
  8. 2AL plus: SP & Chloroquine (n = 4); SP & Quinine (n = 1); SP & Chloroquine & Quinine (n = 1)
  9. 3AL plus: SP (n = 71); Chloroquine (n = 7)
  10. 4AL plus: SP & Chloroquine (n = 11); SP & Quinine (n = 2)